Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 8/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.54 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19049362 | 0.89 | HSD11B1 (0.52) | EPHX2EPHX1HSD11B1THRBATM | |
| SCHEMBL13207060 | 0.86 | HSD11B1 (0.51) | HSD11B1 | |
| SCHEMBL19002252 | 0.85 | EPHX2 (0.60) | EPHX2EPHX1HSD11B1THRBATM | |
| SCHEMBL12039329 | 0.83 | DRD2 (0.50) | HSD11B1THRBATML3MBTL1MEN1 | |
| SCHEMBL20665186 | 0.83 | HSD11B1 (0.50) | EPHX2HSD11B1THRBATML3MBTL1 | |
| SCHEMBL19002258 | 0.83 | HSD11B1 (0.50) | EPHX2EPHX1HSD11B1THRBATM | |
| SCHEMBL18380884 | 0.82 | SMYD3 (0.47) | EPHX1HSD11B1THRBATML3MBTL1 | |
| SCHEMBL7788916 | 0.82 | SMYD3 (0.47) | EPHX1HSD11B1THRBATML3MBTL1 | |
| SCHEMBL7470486 | 0.82 | — | — | |
| SCHEMBL14069430 | 0.81 | EPHX2 (0.49) | EPHX2EPHX1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3642209-B1 | COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY Therapeutics LLC (US) | 2023-11-29 | — | — | EP | disclosed |
| EP-3394056-B1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC (US) | 2021-04-14 | — | — | EP | disclosed |
| WO-2017112777-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC (US) | 2017-06-29 | — | — | WO | disclosed |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | EPHX2 2625/4885EPHX1 1313/4885HSD11B1 1215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.